Latest News-Ascletis Pharma Inc. Mediaroom_Page

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2020-10-12 08:30 7603

Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascleti...

2020-09-14 08:30 3408

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owne...

2020-09-09 18:30 4539

Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen

HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-08-20 20:00 3729

First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-08-17 08:30 3636

Ascletis' All-oral HCV Treatment Approved for Marketing in China

HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-31 08:47 9598

Bridging Study in China Completed for NASH Drug Candidate ASC40

HANGZHOU and SHAOXING, China, July 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-20 08:30 4521

ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial

HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-06-17 20:30 2951

Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication

HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ...

2020-05-13 18:30 2811

Ascletis Receives IND Approval for its HIV Drug ASC09F

HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-04-13 20:00 3168

Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020

HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-04-01 08:30 2645

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

HANGZHOU and SHAOXING, China, March 25, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-03-25 08:28 3031

Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU, China and SHAOXING, China, March 10, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code...

2020-03-10 17:30 3379

Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-02-27 08:00 3475

Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-02-18 08:00 2923

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK...

2020-01-23 09:52 2902

Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout

HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), ...

2019-11-29 08:00 2418

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a...

2019-10-08 08:00 2377

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an inn...

2019-09-30 16:30 993

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an inn...

2019-09-30 16:30 2233